Business Wire

Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors

Share
Some of the content included in this release is not shown due to cookie policy. The external content is hosted by the following providers:
  • cts.businesswire.com
By viewing the external content you accept the terms and conditions of the third party that is hosting the content.

You can change your cookie consent to allow this kind of content permanently or click the button below to allow only the content in this release.

Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medicines by the US Food and Drug Administration.

Mr. Paulsen, who joined Ferring’s Board of Directors1 in July 2021, played a leading role in securing the US approval of Adstiladrin® (nadofaragene firadenovec-vncg), a first-in-class gene therapy offering a new approach to treating a severe form of BCG-unresponsive non-muscle invasive bladder cancer. Another breakthrough for the company came with the US approval of Rebyota™ (fecal microbiota – live jslm), the first FDA-approved microbiota-based live biotherapeutic, for the prevention of recurrence of Clostridioides difficile infection. Ferring was therefore responsible for two out of the eight biological medicine products approved by the FDA’s Center for Biologics Evaluation and Research in 2022.2

Mr. Paulsen’s appointment is one of a number of changes to the Board of Directors marking a new phase in Ferring’s growth development. Lars Rebien Sørensen, who became Executive Chairman in July 2021, will remain on the Board as Vice-Chairman. Mr. Paulsen’s father, Dr. Frederik Paulsen, who held the post of Chairman from 1988 until 2021, continues as Chairman Emeritus of the Ferring Group.

Jean-Frédéric Paulsen said: “I am honoured to take over responsibility for the Ferring Group which was founded by my grandfather Dr. Frederik Paulsen and his wife, Eva Paulsen, in 1950, and chaired by my father for more than 30 years. Under their leadership, Ferring has established a global reputation as a leader in reproductive medicine and maternal health, and in numerous specialty areas of medicine. I look forward to building on our heritage and strong foundations to lead Ferring into an exciting new era as we establish a pioneering presence in areas such as uro-oncology and the microbiome.”

Mr. Paulsen has been Chairman of Ferring Ventures SA and FinVector Oy since 2020, and previously served as Senior Advisor to four Ministers of Economy and Sustainable Development in Georgia. He began his career working at Mars Inc., Coca Cola and Credit Suisse. Mr. Paulsen gained a Master’s degree in Finance from the London School of Economics and Political Science, and is a Fellow of the Chartered Institute of Management Accountants in the UK.

In other significant changes to the Board of Directors, Viviane Monges joins the Board and has been appointed as Chair of the Audit and Finance Committee in place of Hélène Ploix, who has stood down from the Board of Directors. Ms. Monges previously held senior corporate positions in the life sciences and consumer sectors. She was a Chief Financial Officer at Wyeth Pharmaceuticals/Pfizer, Novartis and Galderma before becoming Vice-President Business Excellence Finance & Control at Nestlé.

Henrik Normann also joins Ferring’s Board of Directors, having previously been President and CEO of Nordic Investment Bank, the international financial institution of the Nordic and Baltic countries. Mr. Normann spent much of his career at Danske Bank, starting as a management trainee in 1983 and later becoming Head of Danske Bank in Denmark and Global Head of Danske Markets.

At the same time, Jeffrey Hobbs and Alexandra, Countess of Frederiksborg have stood down from the Board of Directors. All changes are effective from 1st July 2023.

Mr. Sørensen said: “As Vice-Chairman of the Board of Directors, I am pleased to support the new Executive Chairman during a period of transition as he takes on greater responsibilities from the Chairman Emeritus. I would like to welcome the new members of the Board of Directors, and to sincerely thank those who have done so much to drive the company’s long-term strategy, helping more people around the world to build families and live better lives.”

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

References

1 This refers to the Board of Directors of Ferring Holding SA, the parent company of the Ferring Pharmaceuticals group.
2 U.S. Food and Drug Administration. 2022 Biological License Application Approvals. Available at: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2022-biological-license-application-approvals. Last accessed June 21, 2023.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bhavin Vaid
Head of Corporate Communications & Public Affairs
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com

Carine Julen
Manager, Corporate Communications & Public Affairs
+41 76 301 0178 (mobile)
carine.julen@ferring.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES Update on Annual General Meeting Agenda14.3.2025 20:41:00 CET | Press Release

SES S.A. (“SES” or the “Company”) today issued the following statements in relation to the Company’s upcoming Annual General Meeting (“AGM”), taking place on 3 April 2025: Proposed Additions to SES’s Board of Directors The Company is pleased to propose the addition of two new members, Ellen Lord and John Shaw, to its Board of Directors. Ellen Lord is the former Under Secretary of Defense for Acquisition and Sustainment of the United States Department of Defense and has board experience with listed and non-listed companies, including Voyager Space Holdings Inc., National Defense Industrial Association and Defense Technology Initiative. John Shaw is a former Deputy Commander of the U.S. Space Force and first Commander of the USSF Space Operations Command and Combined Forces Space Component Command. The Company believes that adding the unique and valuable experience and skillsets of Ellen and John to its Board, both of whom bring direct experience in U.S. Department of Defense and U.S. Sp

bd-capital raises €430 million for Second Fund14.3.2025 10:35:00 CET | Press Release

bd-capital, the pan-European, operator-led investment firm, is pleased to announce the final closing of its second fund, bd-capital Fund 2 (“Fund 2”), at €430 million. The fund closed more than 20% over its target of €350 million after less than twelve months in the market. With the closing of Fund 2, bd-capital’s assets under management have increased to over €800 million. Commitments to Fund 2 were secured from a diverse cohort of institutional investors, including insurance companies, pension funds, sovereign wealth funds and family offices. In addition to Europe and the Middle East, a significant proportion of capital came from North American investors. bd-capital’s Managing Partners, Andy Dawson and Richard Baker, said: “We are incredibly grateful for the continued support we have received from our existing limited partners and are delighted to have welcomed such a fantastic group of new investors into Fund 2. To have exceeded our fundraising target in a relatively short timeframe

Reply at NVIDIA GTC 2025: How AI Agents and Digital Humans are Redefining Customer Experience14.3.2025 10:00:00 CET | Press Release

Reply, a global systems integrator and consulting firm, specialised in AI-driven solutions and intelligent systems, is taking part in NVIDIA GTC 2025, a premier conference hosted by NVIDIA that is focused on the future of accelerated computing and AI, held from March 17–21 in San Jose, California. As part of the event, Roberto Del Ponte, Associate Partner at Infinity Reply, will take the stage for an insightful panel discussion titled “Customer Service 2.0: Transforming Experiences with AI Agents and Digital Humans” on March 19, 2025, from 11:00 AM to 12:00 PM PT. The panel will explore the evolving role of AI-driven customer interactions, focusing on AI agents and digital humans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250314195701/en/ Reply’s participation in NVIDIA GTC 2025 underscores its commitment to advancing the field of digital humans and emotionally intelligent AI solutions. (Graphic: Business Wire) The disc

Galderma Successfully Placed an Inaugural EUR 500 Million Single Tranche Eurobond and New Dual Tranche CHF 435 Million CHF Bonds14.3.2025 07:00:00 CET | Press Release

Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma (SIX: GALD) has made significant progress on its refinancing strategy to spread out its maturity profile, diversify funding sources and reduce its interest costs, by successfully issuing the following bonds: EUR 500 million bond, with a 5-year maturity and a 3.5% fixed-rate annual coupon CHF 190 million bond, with a 4-year maturity and a 1.4025% fixed-rate annual coupon CHF 245 million bond, with a 8-year maturity and a 1.8098% fixed-rate annual coupon The payment dates are March 20, 2025, for the Eurobond and the CHF bonds. The bonds will be listed on the SIX Swiss Exchange. The EUR transaction was led by BNP Paribas, J.P. Morgan, Mizuho, and Santander as active bookrunners, while the CHF transaction was led by UBS and BNP Paribas. Galderma is rated BBB (stable outlook) by Fitch and Fitch is expect

Cessna Citation X and X+ Customers Benefit From Starlink High-Speed Internet Availability13.3.2025 16:00:00 CET | Press Release

Textron Aviation today announced an additional high-speed internet connectivity solution for the Cessna Citation X and X+ following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250313683324/en/ Textron Aviation announced an additional high-speed internet connectivity solution for the Cessna Citation X and X+ following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. (Photo Credit: Textron Aviation) Beechcraft, Cessna and Hawker customers receive factory-direct suppor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye